« Back
Home /
Modified MMAF

Modified MMAF

Item no.	HY-141594-100mg
Manufacturer	MedChem Express
CASRN	1352202-47-1
Amount	100 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Citations	[1]Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection [published correction appears in Cancer Res. 2010 Feb 1;70(3):1275. Slaga, Dion S [added]]. Cancer Res. 2009;69(6):2358-2364.<br>[2]Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17(1):114-124.
Smiles	O=C(N1CCCCO1)[C@@H](NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@@H](NC)C(C)C)=O)=O)=O)OC)=O)CC3=CNC4=CC=CC=C34
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Available
Product Description	Modified MMAF, an ADC cytotoxin, can be used in the synthesis of Antibody-drug Conjugate (ADC). Modified MMAF can be used for the targeted research of cancer[1].
Shipping	Room temperature
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	840.10
Clinical_Information	No Development Reported
Manufacturers Research_Area	Cancer
Solubility	10 mM in DMSO
Manufacturers Target	Microtubule/Tubulin
Pathway	Cell Cycle/DNA Damage; Cytoskeleton
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Request delivery time